Nykode Therapeutics AS (OSL: NYKD)
6.44
-0.16 (-2.42%)
Aug 30, 2024, 4:25 PM CET
Nykode Therapeutics AS Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
Cash & Equivalents | 136.53 | 162.6 | 206.39 | 216.23 | 183.85 | 10.17 | Upgrade
|
Trading Asset Securities | - | - | - | 12.17 | 24.94 | 21.68 | Upgrade
|
Cash & Short-Term Investments | 136.53 | 162.6 | 206.39 | 228.4 | 208.8 | 31.85 | Upgrade
|
Cash Growth | -21.34% | -21.21% | -9.64% | 9.39% | 555.64% | -77.82% | Upgrade
|
Accounts Receivable | - | - | 2.54 | 23.75 | 18.75 | 0 | Upgrade
|
Other Receivables | 3.49 | 1.07 | 1.79 | 2.41 | 1.34 | 1.26 | Upgrade
|
Receivables | 3.49 | 1.07 | 4.33 | 26.16 | 20.09 | 1.26 | Upgrade
|
Prepaid Expenses | - | 2.01 | 1.15 | 1.3 | 0.15 | 0.07 | Upgrade
|
Other Current Assets | - | - | - | - | -0 | 0 | Upgrade
|
Total Current Assets | 140.02 | 165.68 | 211.87 | 255.86 | 229.03 | 33.17 | Upgrade
|
Property, Plant & Equipment | 9.28 | 10.52 | 9.53 | 9.17 | 0.41 | 0.17 | Upgrade
|
Other Intangible Assets | 0.07 | 0.07 | 0.03 | 0.03 | 0.03 | 0.03 | Upgrade
|
Long-Term Deferred Charges | - | - | - | 0.48 | 0.55 | - | Upgrade
|
Other Long-Term Assets | 30.5 | 31.92 | 0.05 | 0.02 | 0.01 | 0.01 | Upgrade
|
Total Assets | 179.88 | 208.19 | 221.48 | 265.56 | 230.03 | 33.39 | Upgrade
|
Accounts Payable | 3.42 | 1.33 | 2.31 | 2.75 | 1.61 | 1.52 | Upgrade
|
Accrued Expenses | - | 6.08 | 7.58 | 9.3 | 9.68 | 2.47 | Upgrade
|
Current Portion of Leases | 1.4 | 1.46 | 1.15 | 1.35 | 0.28 | 0.06 | Upgrade
|
Current Income Taxes Payable | - | - | 0.08 | 0.03 | - | - | Upgrade
|
Current Unearned Revenue | 7.29 | 8.34 | 19.87 | 16.26 | - | 0.09 | Upgrade
|
Other Current Liabilities | 2.99 | 3.41 | 8 | 1.69 | 1.61 | 0.18 | Upgrade
|
Total Current Liabilities | 15.09 | 20.61 | 38.99 | 31.37 | 13.18 | 4.32 | Upgrade
|
Long-Term Leases | 3.39 | 4.27 | 4.37 | 5.82 | 0.01 | 0.03 | Upgrade
|
Long-Term Deferred Tax Liabilities | 8.44 | 12.05 | 21.08 | 29.4 | 31.13 | - | Upgrade
|
Other Long-Term Liabilities | 0.88 | 0 | 0.03 | 4.91 | 6.86 | 1.4 | Upgrade
|
Total Liabilities | 27.8 | 36.93 | 64.46 | 71.5 | 51.18 | 5.76 | Upgrade
|
Common Stock | 0.37 | 0.37 | 0.34 | 0.33 | 0.33 | 0.32 | Upgrade
|
Additional Paid-In Capital | 128.99 | 128.99 | 83.32 | 81.53 | 60.35 | 59.13 | Upgrade
|
Retained Earnings | 7.73 | 29.56 | 64.71 | 107.46 | 116.87 | -32.91 | Upgrade
|
Comprensive Income & Other | 15 | 12.35 | 8.65 | 4.74 | 1.31 | 1.09 | Upgrade
|
Shareholders' Equity | 152.08 | 171.26 | 157.02 | 194.06 | 178.85 | 27.63 | Upgrade
|
Total Liabilities & Equity | 179.88 | 208.19 | 221.48 | 265.56 | 230.03 | 33.39 | Upgrade
|
Total Debt | 4.79 | 5.73 | 5.51 | 7.17 | 0.28 | 0.09 | Upgrade
|
Net Cash (Debt) | 131.75 | 156.88 | 200.87 | 221.23 | 208.51 | 31.76 | Upgrade
|
Net Cash Growth | -21.35% | -21.90% | -9.20% | 6.10% | 556.60% | -77.89% | Upgrade
|
Net Cash Per Share | 0.41 | 0.52 | 0.69 | 0.77 | 0.70 | 0.11 | Upgrade
|
Filing Date Shares Outstanding | 326.55 | 326.55 | 294.69 | 289.62 | 284.79 | 274.87 | Upgrade
|
Total Common Shares Outstanding | 326.55 | 326.55 | 294.69 | 289.62 | 284.79 | 274.87 | Upgrade
|
Working Capital | 124.93 | 145.07 | 172.89 | 224.49 | 215.85 | 28.86 | Upgrade
|
Book Value Per Share | 0.47 | 0.52 | 0.53 | 0.67 | 0.63 | 0.10 | Upgrade
|
Tangible Book Value | 152.01 | 171.19 | 156.99 | 194.02 | 178.82 | 27.6 | Upgrade
|
Tangible Book Value Per Share | 0.47 | 0.52 | 0.53 | 0.67 | 0.63 | 0.10 | Upgrade
|
Machinery | - | 4.97 | 3.44 | 1.46 | 0.2 | 0.12 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.